A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 11, 2007, Pages 843-851

  Yonemoto, Naohiro ^a   Furuse, Junji ^b   Okusaka, Takuji ^c   Yamao, Kenji ^d   Funakoshi, Akihiro ^e   Ohkawa, Shinichi ^f   Boku, Narikazu ^g   Tanaka, Katsuaki ^h   Nagase, Michitaka ⁱ   Saisho, Hiromitsu ^j   Sato, Tosiya ^a  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL KYUSHU CANCER CENTER   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g SHIZUOKA CANCER CENTER   (Japan)

^h YOKOHAMA CITY UNIVERSITY   (Japan)

ⁱ TOCHIGI CANCER CENTER   (Japan)

^j CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Biliary tract cancer; Chemotherapy; Clinical trial; Retrospective study; Survival

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; CISPLATIN; CISPLATIN DERIVATIVE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; UFT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GALLBLADDER CANCER; HUMAN; INOPERABLE CANCER; JAPAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERITONEUM METASTASIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VATER PAPILLA CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; OXONIC ACID; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TEGAFUR;

EID: 37149044948     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym116     Document Type: Article

References (50)

1. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM.Biliary tract cancers. New Engl J Med 1999; 341:1368-78.
2. Okusaka T.Chemotherapy for biliary tract cancer in Japan. Semin Oncol 2002; 6 (Suppl 20):51-3.
3. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.
4. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984; 54:965-9.
5. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600.
6. Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92:1650-4.
7. Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 2004; 66:138-42.
8. Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, et al. Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology 2006; 70:358-65.
9. Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9:653-6.
10. Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, et al. EORTC Gastro Intestinal Tract Cancer Group: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer 2005; 41:398-403.
11. Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamagni D, Caudana R, et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005; 103:1402-7.
12. Ueno H, Okusaka T, Ikeda K Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004; 91:1769-74.
13. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/ mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56:177-80.
14. Ikeda M, Okusaka T, Ueno H, Morizane C, Furuse J, Ishii H. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 2005; 35:439-43.
15. Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, et al. Early Phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 2006; 36:552-6.
16. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12:183-6.
17. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, et al. Weekly geracitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22:193-8.
18. Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, et al. A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 2004; 27:565-9.
19. Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim. H, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: A phase II study. Jpn J Clin Oncol 2005; 35:68-73.
20. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F. Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 2005; 5:61
21. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmac 2006; 57:647-53.
22. Murad AM, Guimaraes RC, Aragao BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, et al. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. Am J Clin Oncol 2003; 26:151-4.
23. Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: A review of the Princess Margaret Hospital experience. Ann Oncol 2004; 15:770-4.
24. Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, et al. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 2004; 90:1715-19.
25. Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial. Cancer 2005; 103:111-8.
26. Malik IA, Aziz Z, Zaidi SH, Sethuraman G. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol 2003; 26:174-7.
27. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004; 90:1516-20.
28. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16:279-81.
29. Lee GW, Kang JH, Kim HG, Lee JS, Lee JS, Jang JS. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 2006; 29:127-31.
30. Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, et al. A Phase II study of gemcitabine and cisplatin in advahced biliary tract cancer. Cancer 2006; 106:1339-46.
31. Kornek GV, Schnell B, Laengle F, Gruenberger T, Penz M, Karall K, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: A randomised phase II trial. Ann Oncol 2004; 15:478-83.
32. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol 2005; 23:2332-8.
33. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DY, Song SY, et al. Capecitabinc combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 2005; 104:2753-8.
34. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocaminoma: A GERCOR study. Ann Oncol 2004; 15:1339-43.
35. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 2006; 17(Suppl 7): Vii68-vii72.
36. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848-52.
37. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, et al. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: A multicenter phase II study. Oncology 2006; 70:280-4.
38. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Offset publication Geneva: World Health Organization, 1979.
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 63:457-81.
41. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc (Ser B) 1972; 34:187-220.
42. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
43. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 1992; 48:479-95.
44. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 2002; 29 (Suppl 20):40-5.
45. Dingle BH, Rumble RB, Brouwers MC. Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group: The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: A systematic review. Can J Gastroenterol 2005; 19:711-6.
46. Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 1994; 51:515-17.
47. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24:3069-74.
48. Eckel F, Schmid RM. Chemotherapy in advanced biliary hact carcinoma: A pooled analysis of clinical trials. Br J Cancer 2007; 96:896-902.
49. Valle JW, Wasan H, Johnson P, Bridgewater J, Maraveyas A E., Jones, et al. Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinoma (CC) and other biliary tract tumors: A multicenter, randomized, phase II (the UK ABC-01) study. ASCO 2006 Gastrointestinal Cancers Symposium abstract 98; Atlanta, GA, 2006.
50. Boku N, Okusaka T, Furuse J, Ohkawa S, Yamao K, Masumoto T, et al. Phase II study of S-1 in patients with unresectable or recurrent biliary tract cancer (BTC). Ann Oncol 2006; 17(Suppl): Ix3l8.